Archbold’s Oncology Center Offers Prostate Screenings

The American Cancer Society estimates that one in eight men will be diagnosed with prostate cancer in their lifetime.

Prostate cancer is one of the most common types of cancer in men, and it’s predicted that 268,490 new cases of prostate cancer will be diagnosed in 2022.

Experts say risk factors include age, family history, ethnicity and overall health.

Though prostate cancer is a serious disease, the good news is that most men diagnosed will not die from it. In fact, more than 3.1 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

“Prostate cancer can often be found early and in its most treatable stages through two different screening tests,” said Eric Webb, MD, urologist at Urology Associates of Archbold. “A test that measures the amount of prostate-specific antigen (PSA) in a man’s blood is often used along with a physical exam, referred to as a digital rectal exam (DRE) that is performed to check the prostate gland for abnormal growth or enlargement.”

On Thursday, September 15, Dr. Webb will join Archbold radiation oncologists Steve Johnson, MD, and David Saunders, MD, to offer free prostate cancer screenings from 4:30 p.m. to 6:30 p.m. at Archbold’s Singletary Oncology Center. Participants will receive a DRE exam and PSA test during the screen. Results for all tests will be provided at no cost to participants as a clinical outreach effort supporting Archbold’s Core Value of Community Benefit.

“We encourage men in our community over the age of 50 to take advantage of this free screening opportunity, even if they aren’t experiencing any symptoms associated with the disease,” said Dr. Johnson. “Early detection is the key to the successful treatment of prostate cancer.”

For more information on the free prostate cancer screening, please call 229.584.5520. Walk-ins only for the screening event; no appointments are necessary.